DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Wedbush Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $164

Wedbush analyst Liana Moussatos maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $175 to $164.

Benzinga · 03/02/2020 15:00

Wedbush analyst Liana Moussatos maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $175 to $164.